it's always been expected one needs to "hold your nose" when it comes to the PPS movements in MDXG
technically a new range is being established and we have options expiration today
next week I suspect management may "flip some pins" IMHO
If I were management I'd have an end of day plan that uses the buyback to bump us above 10 so the shorts don't get the ability to gather shares using the options
Just my 10 cents
bet you didn't notice the OSIR 10Q after the market close today did ya? Assuming you did -
Anything that strikes you about the report? Notice what was not discussed or mentioned?
Lets see how bright you are smart guy
Busy washing your daddys car I'm betting.
First the company can "buy on close"
Second it was the 10k, my oversight
Third, since your too lazy to read the K and insist on avoiding to answer, let me go ahead and "spoon feed" you with a snippet and the magic three words at the end.
"We expect our research and development expenses to continue to be substantial in the future, as we continue our clinical trial activity for our existing Biosurgery products if and as they advance through the development cycle, and if and as we invest in additional product opportunities and research programs. Clinical trials and preclinical studies are time-consuming and expensive. Our expenditures on current and future preclinical and clinical development programs are subject to many uncertainties. We test our products in several preclinical studies, and we then conduct clinical trials for those candidates that we determine to be the most promising. As we obtain results from clinical trials, we may elect to discontinue or delay trials for some product candidates in order to focus our resources on more promising product candidates. Completion of clinical trials may take several years or more, but the length of time generally varies substantially according to the type, size of trial and intended use of a product candidate."
how_bout, your just such a cleaver, quick witted cheeky sort of fellow aren't ya? You must be so proud.
Also my SUGGESTION to buy shares was just that, suggestive.
Are you familiar with what a call buyer has the "right" to do? I suggest you pick up "options for dummies" since your simply "at a loss"
14:44 EDT - MiMedx's(MDXG) announced on New Year's Eve it received an HHS subpoena related to sales and marketing, and shares have spent all of 2015 in the red. But the stock is much closer to break-even today as the wound-care company says the Justice Department for now isn't getting involved in a lawsuit which prompted the subpoena. But that doesn't mean all is clear. MDXG bear Northland Capital notes its concerns haven't been based on the legal picture, but rather " concerns about the sustainability of Mimedx's(MDXG) growth trajectory," regulatory interpretations "and a changing reimbursement landscape." That as in general, the investment bank repeats prior commentary that "on a macro level, there appear to be questionable sales practices in the field." MDXG rises 8.5% to $11.10, cutting the year's drop to 3.7%.
At least the releases now confess "MDXG bear Northland Capital"
long at 10.60 and have already lost 20 cents
sof - it was not long ago ZLTQ was in big doo doo. It's when the CEO came back that the company and the PPS turned around. The PPS of ZLTQ reflects the unwind of a long held short position and improving fundamental IMO.
MDXG, regardless of all the PPS manipulation, has consistently demonstrated the ability to exceed revenue expectations each and every quarter. ZLTQ can't say the same.
"as was pointed out, it's not the first time or the last time they will receive a bulk order of this type"
pointed out by whom cheeky?
Anything that positively or negatively impacts our companies balance sheet is material and should be easily transparent to shareholders IMO
point out all you want but be mindful this is the message board for MDXG, not all your other holdings
keep in mind a days action does not represent a trend
My final comments to you how_bout
Focus on MDXG (the company, management, etc) that's what this board is for.
If you need someone to talk to get a pet.
becca - the real death knell is CELG could stop funding this tiny company. Without CELG this is a shell company IMO.
No reason for MDXG to bother with this company that operates at a loss and has zero reimbursement process
Really insightful penny
ZIOP made 1.3 million in revenue last year and the other 3 are pharma companies
Keep illustrating to everyone here how little you know or understand what MDXG does
Please keep shorting ....
Be careful when you imply an impending FDA approval (which I believe is close at hand)
Our resident "board cop" home_b will be compelled to call you on your nonsense observations.
don't count on it
half the time you find out more on these message boards that what the company offers for press releases
buying more here and can't wait for the greedy shorts to get the shares they want to cover so we can more on